

2024

英文論文

1. 2024 Ikeda M, Yamashita T, Ogasawara S, **Kudo M**, Inaba Y, Morimoto M, Tsuchiya K, Shimizu S, Kojima Y, Hiraoka A, Nouse K, Aikata H, Numata K, Sato T, Okusaka T, Furuse J: Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. **Liver Cancer** 13:193-202, 2024. (IF=11.600)

2. 2024 Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Burgio V, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M: α -FAtE: a new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma. **Int J Cancer** 154:1043-1056, 2024. (IF=5.700)

3. 2024 Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori

2024

英文論文

- M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A: Safety and efficacy of lenvatinib in very old patients with unresectable hepatocellular carcinoma. **Target Oncol** 19:29-39, 2024. (IF=4.400)
4. 2024 Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, Kanto T, Yoshiji H, Izumi N, **Kudo M**, Koike K: The Impact of COVID-19 on the Diagnosis and Treatment of HCC: Analysis of a Nationwide Registry for Advanced Liver Diseases (REAL). **Sci Rep** 14:282696, 2024. (IF=3.800)
5. 2024 Celsa C, Cabibbo G, Fulgenzi C, Scheiner B, d'Alessio A, Mangredi GF, Nishida N, Ang C, Marron U, Saeed A, Wietharn B, Pinter M, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle PR, **Kudo M**, Rimassa L, Singal AG, El Tomb P, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Piscaglia F, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini PF, De Napoli M, Ermacora P, Antonuzzo L, Schinzari G, Verderame F, Zustovich F, Ficorella C, Morelli MF, Battelli N, Negrini G, Grossi F, Bordonaro R, Sabbatini R, Banzi M, Migliorino MR, Laera L, Russo A, De Giorgi U, Cavanna L, Soraru M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Camma C, Cortellini A, Pinato DJ: Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours. **J Hepatol** 80:431-442, 2024. (IF=26.800)
6. 2024 Takenaka M, Lee TH, **Kudo M**: Recent advances in metallic stents used in the stent-in-stent method for hilar malignant biliary obstruction. **Dig Endosc** 36:370-372, 2024. (IF=5.000)
7. 2024 Otuska Y, Minaga K, **Kudo M**, Watanabe T: Role of leucine-rich

2024

英文論文

- repeat kinase 2 in severe acute pancreatitis. **Front Immunol** 15:1364839, 2024. (IF=5.700)
8. 2024 Hara A, Minaga K, Otsuka Y, Tanaka H, Takenaka M, **Kudo M**: Emergency digital cholangioscopy-assisted electrohydraulic lithotripsy for basket impaction with an entrapped bile duct stone. **Endosc Int Open** 12:E271-E273, 2024. (IF=2.200)
9. 2024 Hagiwara S, Tanizaki J, Hayashi H, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy. **Cancer Rep** 7:e1960, 2024. (IF=1.500)
10. 2024 **Kudo M***: Objective response to systemic therapy is a strong predictor of overall survival in patients with unresectable hepatocellular carcinoma. **Liver Cancer** 13:1-5, 2024. <https://doi.org/10.1159/000535516> (IF=11.600)
11. 2024 Aoki T, **Kudo M***, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N: Incidence of hyper progressive disease in combination immunotherapy and anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular carcinoma. **Liver Cancer** 13:56-69, 2024. <https://doi.org/10.1159/000531024> (IF=11.600)
12. 2024 **Kudo M***, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y: A Phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable Intermediate-stage hepatocellular carcinoma: TACTICS-L trial. **Liver Cancer** 13:99-112, 2024. <https://doi.org/10.1159/000531377> (IF=11.600)

2024

英文論文

13. 2024 Kariyama K, Nouse K, Hiraoka A, Toyoda H, Tada T, Tsuji K, Ishikawa T, Hatanaka T, Itobayashi E, Takaguchi K, Tsutsui A, Naganuma A, Yasuda S, Kakizaki S, Wakuta A, Shiota S, **Kudo M**, Kumada T: Treatment options for solitary hepatocellular carcinoma ≤ 5 cm: Surgery vs ablation: A multicenter retrospective study. **J Liver Cancer** 24:71-80, 2024. (IF=0.000)
14. 2024 Masuta Y, Minaga K, Otsuka Y, Okai N, Hara A, Masaki S, Nagai T, Honjo H, **Kudo M**, Watanabe T: Cytokine and chemokine profiles in ulcerative colitis relapse after coronavirus disease 2019 vaccination. **J Clin Biochem Nutr** 74:127-135, 2024. (IF=2.000)
15. 2024 Okai N, Masuta Y, Otsuka Y, Hara A, Masaki S, Kamata K, Minaga K, Honjo H, **Kudo M**, Watanabe T: Crosstalk between NOD2 and TLR2 suppresses the development of TLR2-mediated experimental colitis. **J Clin Biochem Nutr** 74:146-153, 2024. (IF=2.000)
16. 2024 Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, **Kudo M**, Finn RS: Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. **Nat Rev Clin Oncol** 21:294-311, 2024. (IF=81.100)
17. 2024 Trevisani F, Vitale A, **Kudo M**, Kulik L, Park JW, Pinato DJ, Cillo U: Merits and boundaries of the Barcelona Clinic Liver Cancer staging and treatment algorithm: learning from the past to improve the future with a novel proposal. **J Hepatol** 80:661-669, 2024. (IF=26.800)
18. 2024 Piscaglia F, Ikeda K, Cheng AL, **Kudo M**, Ikeda M, Breder V, Ryoo BY, Modi K, Ren M, Ramji Z, Sung MW: Association between treatment-emergent hypertension and survival with lenvatinib treatment for patients with hepatocellular carcinoma in REFLECT study. **Cancer** 130:1281-1291, 2024. (IF=6.100)

2024

英文論文

19. 2024 **Kudo M***: Urgent global need for PIVKA-II and AFP-L3 measurements for surveillance and management of hepatocellular carcinoma. **Liver Cancer** 13:113-118, 2024. (IF=11.600)
20. 2024 Rimini M, Stefanini B, Tada T, Suda G, Shimose S, **Kudo M**, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavorane M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Solda C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyada H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F: Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab. **Liver Int** 44:1108-1125, 2024. (IF=6.000)
21. 2024 Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK, for the HIMALAYA investigators: Four-year overall survival update from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. **Ann Oncol** 35:448-457, 2024. (IF=56.700)
22. 2024 Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa

2024

英文論文

- C, Yokohama K, Nishikawa H, Nishimura T, Shimada N, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Aoki T, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, **Kudo M**, Kumada T: Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter study. **Hepatol Res** 54:382-391, 2024. (IF=3.900)
23. 2024 Okai N, Otsuka Y, Masaki S, **Kudo M**, Watanabe T: Necrotizing fasciitis of the serratus anterior in a patient treated with infliximab and prednisolone for ulcerative colitis and rheumatoid arthritis. **Cureus** 16:e59346, 2024. (IF=1.200)
24. 2024 Lyshchik A, Fetzer D, Kono Y, Wilson S, Dietrich CF, Clevert D, Meloni M, Jang HJ, Kim TK, Lee JM, Minami Y, **Kudo M**, Piscaglia F: Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024. **Radiology** 11:e232369, 2024. (IF=12.100)
25. 2024 Thornton LM, Abi-Jaoudeh N, Lim HJ, Malagari K, Spieler BO, **Kudo M**, Finn RS, Lencioni R, White SB, Kokabi N, Jeyarajah DR, Chaudhury P, Liu D: Combination and optimal sequencing of systemic and locoregional therapies in hepatocellular carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. **J Vasc Interv Radiol** 35:818-824, 2024. (IF=2.600)
26. 2024 Hagiwara S, Takase T, Oda I, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: Hereditary hemorrhagic telangiectasia with hepatic arteriovenous shunt diagnosed due to liver damage. **Clin J Gastroenterol** 17:477-483, 2024. (IF=0.800)
27. 2024 Otsuka Y, Minaga K, Hara A, Yamao K, Takenaka M, Chikugo T, **Kudo M**: Early diagnosis of pancreatic cancer via pancreatic

2024

英文論文

- juice cytology with a cell-block method in a patient with altered anatomy. **Endosc Int Open** 12:E764-E766, 2024. (IF=2.200)
28. 2024 Kawano K, Takenaka M, Kawano R, Moriguchi T, Mine K, Nishi K, **Kudo M**: A technique for preventing clip snagging during the use of a rotating function endoscopic clip. **Endoscopy** 56:E502-E503, 2024. (IF=11.500)
29. 2024 Omoto S, Takenaka M, Takashima K, Komeda Y, **Kudo M**: The "echo-free space" technique: A safe and reliable method for endoscopic ultrasound scope insertion into the esophagus. **Endoscopy** 56:E500-E501, 2024. (IF=11.500)
30. 2024 Kamata K, **Kudo M**, Watanabe T: Indigo naturalis as a promising novel treatment for type 2 autoimmune pancreatitis. **Pancreatology** 24:665-666, 2024. (IF=2.800)
31. 2024 **Kudo M***: Immune checkpoint inhibitors plus snti-VEGF/Tyrosine kinase inhibitors combined with TACE (Triple therapy) in unresectable hepatocellular carcinoma. **Liver Cancer** 13:227-234, 2024. (IF=11.600)
32. 2024 Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Ueshima K, Minami Y, Tsurusaki M, Nakai T, Sakamoto M, Nishio K, **Kudo M**: Two distinct characteristics of immune microenvironment in human hepatocellular carcinoma with Wnt/ β -catenin mutations. **Liver Cancer** 13:285-305, 2024. DOI:101159/000533818. (IF=11.600)
33. 2024 Komeda Y, Ishikawa H, Yoshida T, Ushiyama M, Yoshida S, Nomura K, Kono M, Omoto S, Takenaka M, Hagiwara S, Kashida H, **Kudo M**: Familial adenomatous polyposis with atypical clinical morphology and genetic variants. **Intern Med** 63:1075-1079, 2024. (IF=1.000)
34. 2024 Honjo H, Minaga K, Hara A, Takada R, Otsuka Y, Masuta Y,

2024

英文論文

- Masaki S, Matsui S, **Kudo M**, Watanabe T: Circumferential stenosis of the second part of the duodenum caused by eosinophilic gastroenteritis. **Intern Med** 63:1087-1092, 2024. (IF=1.000)
35. 2024 Rimassa L, Li D, Ikeda M, Yarchoan M, Ryou BY, Kossler T, Lim HY, Kwiatkowski M, Chang TT, Kim JH, Casadei-Gardini A, **Kudo M**, Ren Z, Calvo MV, Llovet JM, Zhang Y, Hatogai K, Siegel AB, Cheng AL: Coformulated quavonlimab and pembrolizumab (pembro) in combination with lenvatinib (lenva) as first-line (1L) therapy for patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 2 KEYSTEP-004 study. **J Clin Oncol** 42:484, 2024. https://doi.org/10.1200/JCO.2024.42.3_suppl.484 (IF=42.100)
36. 2024 **Kudo M***: A changing role of transarterial chemoembolization in the era of immune checkpoint inhibitor plus anti-VEGF/TKI plus yransarterial chemoembolization: From total embolization to partial embolization (Immune Boost Transarterial Chemoembolization). **Liver Cancer** 13:335-343, 2024. (IF=11.600)
37. 2024 Otsuka Y, Masuta Y, Minaga K, Okai N, Hara A, Takada R, Masaki S, Kamata K, Honjo H, Yamashita K, **Kudo M**, Watanabe T: Reciprocal regulation of protein arginine deiminase 2 and 4 expression in the colonic mucosa of ulcerative colitis. **J Clin Biochem Nutr** 75:46-53, 2024. (IF=2.000)
38. 2024 Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts

2024

英文論文

for HCC URELPEC) Study Group: Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial.

Aliment Pharm Ther 60:233-245, 2024. (IF=6.600)

39. 2024 Persano M, Rimini M, Tada T, Suda G, Shimose S, **Kudo M**, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A: Adverse events as potential predictive factors of activity in patients with advanced HCC treated with atezolizumab plus bevacizumab. **Target Oncol** 19:645-659, 2024. (IF=4.400)
40. 2024 Teufel A, **Kudo M**, Qian Y, Daza J, Rodriguez I, Reissfelder C, Ridruejo E, Ebert MP: Current trends and advancements in the management of hepatocellular carcinoma. **Digest Dis** 42:349-360, 2024. (IF=2.000)
41. 2024 Taouli B, Ba-Ssalamah A, Chapiro J, Chhatwal J, Fowler K, Kang TW, Knobloch G, Koh DM, **Kudo M**, Lee JM, Murakami T, Pinato D, Ringe KI, Song B, Tabrizian P, Wang J, Yoon JH, Zeng M, Zhou J, Vilgrain V: Correction to: Consensus report from the 10th global forum for liver magnetic resonance imaging: developments in HCC management. **Eur Radiol** 34:4845-4846, 2024. (IF=4.700)

2024

英文論文

42. 2024 Matsui S, Kashida H, Takita M, **Kudo M**: Endoscopic glue injection therapy with N-butyl-2-cyanoacrylate for bleeding from isolated large rectal varices. **Endoscopy** 56:E738-E739, 2024. (IF=11.500)
43. 2024 Rimini M, Real V, Amadeo E, Vitiello F, **Kudo M**, Tada T, Suda G, Shimose S, Lonardi S, Finkelmeier F, Masi G, Antonuzzo L, Marra F, Iavarone M, Cabibbo G, Foschi FG, Silletta M, Sacco R, Rapposelli IG, Scartozzi M, Nicoletta P, Aldrighetti L, Persano M, Rossari F, Masi G, Antonuzzo L, Nicoletta P, Scartozzi M, Cascinu S, Casadei-Gardini A, Presa J: Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first line lenvatinib or atezolizumab plus bevacizumab. **Sci Rep** 14:20200, 2024. doi: 10.1038/s41598-024-70928-z (IF=3.800)
44. 2024 Yamazaki T, Kamata K, Hyodo T, Im SW, Tanaka H, Yoshida A, Fukunaga T, Omoto S, Minaga K, Takenaka M, **Kudo M**: Utility of contrast-enhanced harmonic endoscopic ultrasonography to diagnose pancreaticobiliary maljunction. **Dig Dis Sci** 69:3008-3014, 2024. (IF=2.500)
45. 2024 Trevisani F, Vitale A, Colli A, **Kudo M**, Kulik L, Park JW, Pinato DJ, Cillo U: Reply to: "Evidence and choice: The BCLC vision for tailoring clinical decision-making" **J Hepatol** 81: e178-180, 2024. (IF=26.800)
46. 2024 Rossari F, Tada T, Suda G, Shimose S, **Kudo M**, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H,

2024

英文論文

- Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M: Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study. **Liver Cancer** 13:522-536, 2024. (IF=11.600)
47. 2024 Otsuka Y, Minaga K, Hara A, Masuta Y, Takenaka M, Chikugo T, **Kudo M**: Detective flow imaging endoscopic ultrasound for locating optimal puncture site for a poorly vascularized pancreatic mass. **Endosc Int Open** 12:E1063-E1064, 2024. (IF=2.200)
48. 2024 Omaru N, Otsuka Y, Hara A, Kurimoto M, Okai N, Masuta Y, Masaki S, Kamata K, Minaga K, Honjo H, Arai Y, Yamashita K, **Kudo M**, Watanabe T: Microbe-associated molecular patterns derived from fungi and bacteria promote IgG4 antibody production in patients with type 1 autoimmune pancreatitis. **Cytokine** 183:156748, 2024. doi: 10.1016/j.cyto.2024.156748 (IF=3.700)
49. 2024 Fulgenzi CAM, Scheiner B, D'Alessio A, Mehan A, Manfredi GF, Celsa C, Nishida N, Ang C, Marron TU, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang YH, Lee PC, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, Von Felden J, Schulze K, Wege H, Galle P, Pirisi M, Park JW, **Kudo M**, Rimassa L, Singal AG, Ulahannan S, Parisi A, Chon HJ, Hsu WF, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini E, Cortellini A, Pinato DJ: Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction. **JAMA Oncol** 10:1253-1258, 2024. (IF=22.500)

2024

英文論文

50. 2024 Hara A, Minaga K, Otsuka Y, Masuta Y, Nakamura Y, Kajiyama H, Park AM, **Kudo M**, Watanabe T: An autopsy case of gas gangrene, massive intravascular hemolysis, and cytokine storm due to *Clostridium perfringens* type A infection. **IDCases** 36:e02085, 2024. (IF=1.100)
51. 2024 Masaki S, Masuta Y, Honjo H, **Kudo M**, Watanabe T: NOD2-mediated dual negative regulation of inflammatory responses triggered by TLRs in the gastrointestinal tract. **Front Immunol** 15:1433620, 2024. (IF=5.700)
52. 2024 Kawai M, Fukuda A, Otomo R, Obata S, Minaga K, Asada M, Umemura A, Uenoyama Y, Hieda N, Morita T, Minami R, Marui S, Yamauchi Y, Nakai Y, Takada Y, Ikuta K, Yoshioka T, Mizukoshi K, Iwane K, Yamakawa G, Namikawa M, Sano M, Nagao M, Maruno T, Nakanishi Y, Hirai M, Kanda N, Shio S, Itani T, Fujii S, Kimura T, Matsumura K, Ohana M, Yazumi S, Kawanami C, Yamashita Y, Marusawa H, Watanabe T, Itoh Y, **Kudo M**, Seno H: Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning. **Brit J Cancer** 131:1158-1168, 2024. (IF=6.400)
53. 2024 Masaki S, Honjo H, Kurimoto M, Okai N, Otsuka Y, Masuta Y, Kamata K, Minaga K, **Kudo M**, Watanabe T: Concurrent occurrence of ulcerative duodenitis and ulcerative colitis displaying unique responses to golimumab and Ustekinumab. **Clin J Gastroenterol** 17:854-860, 2024. (IF=0.800)
54. 2024 Sekai I, Minaga K, Hara A, Otsuka Y, Masuta Y, Shigeoka H, Watanabe T, **Kudo M**: Transmesenteric internal hernia: an unexpected adverse event induced by colonoscopy. **Clin J Gastroenterol** 17:861-865, 2024. (IF=0.800)
55. 2024 Badhrinarayanan S, Cotter C, Zhu H, Lin YC, **Kudo M**, Li D: IMbrave152/SKYSCRAPER-14: A phase III study of atezolizumab, bevacizumab, and tiragolumab in advanced

2024

英文論文

- hepatocellular carcinoma. **Future Oncol** 20:2049-2057, 2024. (IF=3.000)
56. 2024 Kono M, Komeda Y, Kawakami H, Hagiwara S, Tribonias G, Handa K, Omoto S, Takenaka M, Kashida H, Tsuji N, **Kudo M**: JAK inhibitor upadacitinib induces remission in refractory immune-related colitis triggered by CTLA-4 and PD-1 inhibitor combination therapy in malignant pleural mesothelioma: A case report. **Cancer Rep** 7:e70032, 2024. (IF=1.500)
57. 2024 Kawano K, Takenaka M, Kawano R, Kagoshige D, Mine K, Nishi K, **Kudo M**: Injection tip method to improve poor visibility during over-the-scope clip procedure. **Endoscopy** 56:E898-E900, 2024. (IF=11.500)
58. 2024 **Kudo M***: Nivolumab plus Ipilimumab: A novel first-line combination immunotherapy for unresectable hepatocellular carcinoma. **Liver Cancer** 13:459-467, 2024. (IF=11.600)
59. 2024 Finn RS, Qin S, Piscaglia F, Vogel A, Evans TRJ, Knox JJ, López CL, Ramji Z, Ren M, Mody K, **Kudo M**: Characterization of tumor responses in patients with unresectable hepatocellular carcinoma treated with lenvatinib in the Phase 3 randomized trial: REFLECT. **Liver Cancer** 13:537-547, 2024. (IF=11.600)
60. 2024 Finn RS, **Kudo M**, Barnes G, Meyer T, Boisserie F, Abdrashitov R, Chen Y, Li S, Vogel A, Qin S, Zhu AX: Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study. **Liver Cancer** 13:548-560, 2024. (IF=11.600)
61. 2024 Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama

2024

英文論文

- H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tanaka T, Tada F, Nouse K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, **Kudo M**, Kumada T, on behalf of the Real-life Practice Experts for HCC Study Group and HCC 48 Group: Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients. **Aliment Pharm Ther** 60:1361-1373, 2024. (IF=6.600)
62. 2024 Balcar L, Scheiner B, Fulgenzi CAM, D'Alessio A, Pomej K, Roig MB, Meyer EL, Cheon J, Nishida N, Lee PC, Wu LL, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal YI, Chamseddine S, Wietham B, Parisi A, Huang YH, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle PR, Stauber R, **Kudo M**, Singal AG, Itani A, Ulahannan SV, Parikh ND, Cortellini A, Kaseb A, Rimassa L, Chon HJ, Pinato DJ, Pinter M: A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma. **JHEP reports** 6:100982, 2024. (IF=9.500)
63. 2024 Hagiwara S, Nakagawa K, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: A case of a splenic artery aneurysm and focal nodular hyperplasia associated with an abdominal vascular abnormality of hereditary hemorrhagic telangiectasia. **Intern Med** 63:2787-2793, 2024. (IF=1.000)
64. 2024 Hara A, Watanabe T, Minaga K, Yoshikawa T, Kurimoto M, Sekai I, Masuta Y, Takada R, Otsuka Y, Kamata K, Takamura S, **Kudo M**, Strober W: A positive cytokine/chemokine feedback loop establishes plasmacytoid dendritic cell-driven autoimmune pancreatitis in IgG4-related disease. **JCI Insight** 9:e167910, 2024. (IF=6.300)

2024

英文論文

65. 2024 Yoshikawa T, Minaga K, Hara A, Sekai I, Otsuka Y, Takada R, Kamata K, Watanabe T, **Kudo M**: A unique profile of serum cytokines in type 1 autoimmune pancreatitis and chronic rhinosinusitis. **Asian Pac J Allergy Immunol** 42:154-158, 2024. doi: 10.12932/AP-311020-0990 (IF=2.300)
66. 2024 Otsuka Y, Sekai I, Masuta Y, Minaga K, Watanabe T, **Kudo M**: Clinical practice guidelines for acute pancreatitis in the United States and Japan: similarities and differences. **Hepatobil Surg Nutr** 13, 869-872, 2024. (IF=6.100)
67. 2024 El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, **Kudo M**, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B: Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. **Ann Oncol** 35:381-391, 2024. (IF=56.700)
68. 2024 Melero I, Yau T, Kang YK, Kim TY, Santoro A, **Kudo M**, Hou MM, Matilla A, Tovoli F, Knox J, He AR, El-Rayes B, Acosta-Rivera M, Lim HY, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry AB: Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. **Ann Oncol** 35:537-548, 2024. (IF=56.700)
69. 2024 Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguch S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, **Kudo M**^{*}, Cheng AL: Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab. **J Clin Oncol** 42:4060-4070, 2024.

2024

英文論文

(IF=42.100)

70. 2024 Hagiwara S, Ida H, Chikugo T, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Matsubara T, **Kudo M**: Peliosis hepatis complicated by scleroderma and rapidly progressing to liver failure. **Intern Med** 63:3171-3178, 2024. (IF=1.000)
71. 2024 Okamoto A, Kamata K, Yamazaki T, Omoto S, Minaga K, Takenaka M, **Kudo M**: Comparison of bispectral index-guided endoscopic ultrasonography with continuous versus intermittent infusion of propofol: a retrospective study in Japan. **Clin Endosc** 57:814-820, 2024. (IF=2.100)
72. 2024 Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, **Kudo M**, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y: Evaluation of the associations of interleukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a Caucasian genome-wide association study. **Hepatol Res** 54:1215-1225, 2024. (IF=3.900)
73. 2024 Hagiwara S, Oda I, Ueshima K, Komeda Y, Nishida N, Yoshida A, Yamamoto T, Omaru N, Matsubara T, **Kudo M**: A case of fibrolamellar hepatocellular carcinoma in which tumor control was achieved by re-administering atezolizumab and bevacizumab. **Cancer Rep** 7:e70090, 2024. (IF=1.500)
74. 2024 **Kudo M***: Challenges in adjuvant immunotherapy after resection or ablation for hepatocellular carcinoma at high-risk of recurrence. **Liver Cancer** 13:573-578, 2024. (IF=11.600)
75. 2024 **Kudo M***, Tsuchiya K, Yamashita T, Koga H, Nakagawa Y, Ikeda M: Reply to the Letter regarding "Impact of bevacizumab being

2024

英文論文

- skipped due to adverse events of special interest for bevacizumab in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: An exploratory analysis of the Phase III IMbrave150 study. **Liver Cancer** 13:671-673, 2024. (IF=11.600)
76. 2024 Hou J, Berg T, Vogel A, Piraqtvisuth T, Trojan J, De Toni EN, **Kudo M**, Malinowsky K, Findeisen P, Hegel JK, Schöning W, Madin K, Kroeniger K, Chan HLY, Sharma A: Comparative evaluation of multimarker algorithms for early-stage HCC detection in multicenter prospective studies. **JHEP Reports** 7:101263, 2024. (IF=9.500)
77. 2024 **Kudo M***: Systemic therapy combined with locoregional therapy in intermediate-stage hepatocellular carcinoma. **Intervent Radiol**, 2024.
<https://doi.org/10.22575/interventionalradiology.2023-0035>
(IF=0.000)
78. 2024 Wu M, Fulgenzi CAM, D'Alessio A, Cortellini A, Celsa C, Manfredi GF, Stefanini B, Wu L, Huang YH, Saeed A, Pirozzi A, Pressiani T, Rimassa L, Schoenlein M, Schulze K, von Felden J, Mohamed Y, Kaseb AO, Vogel A, Roehlen N, Silletta M, Nishida N, **Kudo M**, Vivaldi C, Balcar L, Scheiner B, Pinter M, Singal AG, Glover J, Ulahannan S, Foerster F, Weinmann A, Galle PR, Parikh ND, Hsu WF, Parisi A, Chon HJ, Pinato DJ, Ang C: Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab. **JHEP Rep** 7:101232, 2024. doi: 10.1016/j.jhepr.2024.101232. (IF=9.500)